Biogen shares fell on January 12 after the Centers for Medicare and Medicaid Services (CMS) issued its draft national coverage decision for the company’s controversial Alzheimer’s drug Aduhelm.
If you are not happy with the results below please do another search
50 search results for:
Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.
The Biden administration on January 12 announced a new set of measures to keep classes open, including doubling COVID-19 testing capacity in schools with 10 million more tests, as the Omicron variant spreads rapidly through the United States.
Pfizer Inc. said on Wednesday booster doses of the company’s COVID-19 vaccine can be administered along with its pneumonia vaccine and produced strong safety and immune responses in people aged 65 and above in a late-stage study.
India’s Bharat Biotech said on January 12 a booster shot of the company’s Covaxin COVID-19 vaccine administered six months after the last of two doses neutralizes both the Omicron and Delta variants of the coronavirus.
Japan recorded a surge in new coronavirus cases on January 12, with infections reaching four-month highs in the major metropolitan areas of Tokyo and Osaka as the Omicron variant spreads.
President Joe Biden and top health officials on January 11 defended the government’s response to the unrelenting pandemic as daily U.S. COVID-19 cases reached a new high, largely fueled by the highly contagious Omicron variant.
The U.S. Food and Drug Administration on January 11 amended the fact sheet for Johnson & Johnson’s COVID-19 vaccine to include a rare risk of immune thrombocytopenia, a bleeding disorder.
The U.S. government’s Medicare program on January 11 said it plans to cover Alzheimer’s treatments including Biogen Inc.’s Aduhelm, with some conditions.
M Booth Health named Stacey Bernstein its new CEO on the heels of the global health communications consultancy’s strongest performing year marked by double-digit growth and multi-million dollar account wins. Bernstein replaces Tim Bird as he transitions into a consultative role.